Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 3, May-June, p. 403–408

doi: 10.17219/acem/41048

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Effects of Thalidomide Combined with Interferon on Inhibiting Kasumi-1 Cell Proliferation

Hao Xu1,A,B,C,D, Ruihua Mi1,A,C,E, Ruihua Fan1,B,C,E, Qingsong Yin1,A,C,E, Xudong Wei1,A,C,D,F

1 Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, China

Abstract

Background. Our previous clinical observations proved that the combination of thalidomide and interferon (IFN) had certain effects in relapsed or refractory AML.
Objectives. The aim of this study was to investigate the effects and its mechanism of thalidomide and IFN on inhibiting the proliferation of Kasumi-1 cells.
Material and Methods. Thalidomide, IFN and a combination of both drugs were used to treat Kasumi-1 cells. The inhibition of cell proliferation and the apoptosis rate were measured. Vascular endothelial growth factor levels and the expression of apoptosis-related proteins were detected by ELISA and Western blotting, respectively.
Results. Thalidomide and IFN could both inhibit Kasumi-1 cell proliferation in a dose-dependent manner. When Kasumi-1 cells were treated with thalidomide 350 μg/mL or IFN1400 U/mL for 48 h, the proliferation inhibition rates were (48.8 ± 4.64)% and (50.19 ± 2.59)% and the rates of apoptosis were (14.68 ± 2.61)% and (21.71 ± 0.71)%, respectively; when treated with a combination, the cell proliferation inhibition rate and apoptotic rate were statistically significantly higher than both the control group and the groups treated with a single drug. The ELISA assay revealed that both 350 μg/mL of thalidomide and 1400 U/mL of IFN could reduce the VEGF levels in cell culture supernatants; the two-drug combination group had a further decreased VEGF concentration. Forty-eighthour treatment of thalidomide 350 μg/mL and IFN 1400 U/mL could significantly decrease Bcl-2 expression and increase the expression levels of phosphor-P38, BAX, cytochrome c, and cleaved caspase-3, -8, and -9 as compared to the control group. The combination group exhibited significantly greater extents of reduction in Bcl-2 protein and increases in p-P38, BAX, and cytochrome c, and cleaved caspase-3, -8, and -9 protein expression as compared to the single drug groups.
Conclusion. Thalidomide and IFN can synergistically inhibit Kasumi-1 cell proliferation, which is possibly achieved through the mitochondrial and death receptor pathways and through the activation of the P38 signaling pathway to induce apoptosis and by inhibiting Kasumi-1 cell autocrine VEGF secretion.

Key words

acute myeloid leukemia, interferon, thalidomide, Kasumi-1 cells

References (16)

  1. Steins MB, Padró T, Bieker R, Ruiz S, Kropff M, Kienast J, Kessler T, Buechner T, Berdel WE, Mesters RM: Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002, 99, 834–839.
  2. Hill NO, Pardue A, Khan A, Aleman C, Hilario R, Hill JM: Clinical trials of human leukocyte interferon in malignancy. Tex Rep Biol Med 1981–1982, 41, 634–640.
  3. Arellano ML, Langston A, Winton E, Flowers CR, Waller EK: Treatment of relapsed acute leukemia after allogeneic transplantation: A single center experience. Biol Blood Marrow Transplant 2007, 13, 116–123.
  4. McSweeney EN, Worman CP, Tsakona CP, Jewel AP, Hoffbrand AV, Milligan DW, Burnett AK, Lewis ML, Goldstone AH: Low-dose recombinant alfa-2a-interferon: A feasible maintenance therapy in acute myeloid leukaemia in the older patient. Acta Haematol 1993, 89, 1–5.
  5. Ai H, Zhang Y, Wei X, Wang P, Mi R, Song Y: Thalidomide in combination with interferon and interleukin 2 in the induction therapy for relapsed refractory acute myeloid leukemia: Two case report and literature review. Chin J Hematol 2014, 35, 954–956.
  6. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993, 81, 3091–3096.
  7. Cory S, Huang DC, Adams JM: The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene 2003, 22, 8590–8607.
  8. Sharpe JC, Arnoult D, Youle RJ: Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta 2004, 1644, 107–113.
  9. Cryns V, Yuan J: Protease to die for. Genes Dev 1998, 12, 1551–1570.
  10. Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F, Majchrzak B, Fujita S, Fish EN, Platanias LC: The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem 2001, 276, 28570–28577.
  11. Lu M, Zhang W, Li Y, Berenzon D, Wang X, Wang J, Mascarenhas J, Xu M, Hoffman R: Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol 2010, 38, 472–480.
  12. Lee CY, Tien HF, Hu CY, Chou WC, Lin LI: Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia. Br J Cancer 2007, 97, 877–882.
  13. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M: Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999, 94, 3717–3721.
  14. De Bont ES, Fidler V, Meeuwsen T, Scherpen F, Hählen K, Kamps WA: Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002, 8, 2856–2861.
  15. Zhao H, Wei X, Yin Q, Song Y: Thalidomide combined with interferon in relapsed or refractory mantle cell lymphoma: Two cases report and literatures review. Chin J Hematol 2012, 33, 776–777.
  16. Hao Q, Wei X, Yin Q, Mi R, Yuan F, Ai H, Wang P, Li Y, Zhang L, Song Y: Thalidomide combined with interferon in 12 cases of relapsed or refractory mantle cell lymphoma. Chin J Hematol 2014, 35, 1013–1015.
© Wroclaw Medical University